Form 4: Alphatec Awards General Counsel Significant RSU Grants

Alphatec Holdings, Inc. granted its General Counsel, Tyson Eliot Marshall, a substantial number of restricted stock units (RSUs) on February 25, 2026, tied to performance and future vesting schedules.

Summary

• Tyson Eliot Marshall, General Counsel & Corporate Secretary of Alphatec Holdings, Inc. (ATEC), was awarded a total of 387,770 Restricted Stock Units (RSUs) on February 25, 2026.
• This includes 205,094 performance-based RSUs for satisfying fiscal year 2025 performance criteria, vesting in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
• An additional 84,918 RSUs were awarded, vesting in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029.
• 12,840 RSUs were granted in lieu of a portion of the 2025 cash bonus, vesting on December 4, 2026.
• Two separate awards of up to 42,459 performance-based RSUs each were granted, contingent on achieving specific stock price targets ($25.00/share by December 31, 2028, and $36.00/share by December 31, 2030) and operational metrics by December 31, 2028, or December 31, 2030.
• Each RSU represents a contingent right to receive one share of Alphatec's common stock.
• Following these transactions, Mr. Marshall's direct beneficial ownership of common stock (including unvested RSUs reported as non-derivative) is 648,294 shares, plus 84,918 derivative RSUs.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting management's confidence in future performance and a commitment to aligning executive incentives with long-term shareholder value, despite the inherent dilution from RSU grants.

Positives

• The significant RSU grants demonstrate Alphatec's commitment to retaining and incentivizing key management personnel like the General Counsel.
• A portion of the RSUs (205,094 units) was awarded based on the satisfaction of performance criteria for fiscal year 2025, indicating successful achievement of company goals.
• Performance-based RSUs tied to stock price targets ($25.00 and $36.00 per share) align management's interests with long-term shareholder value creation.

Negatives

• The issuance of a substantial number of RSUs, once vested and converted to common stock, will result in dilution for existing shareholders, though this is a common practice for executive compensation.

Future Outlook

The filing indicates a forward-looking compensation strategy, with significant RSU awards tied to future vesting schedules extending through March 2029 and performance targets for stock price and operational metrics extending through December 2030. These performance targets suggest management's internal expectations for substantial stock price appreciation to $25.00 and $36.00 per share, and continued operational improvements over the next several years.

Industry Context

StockSavvy.ai notes that performance-based RSU grants are a standard practice in the medical technology and broader corporate sectors to align executive incentives with long-term shareholder value. The specific stock price targets of $25.00 and $36.00 per share for Alphatec (ATEC) suggest a strong belief in the company's growth trajectory, potentially reflecting anticipated market penetration, product innovation, or strategic acquisitions within the spine surgery market, where Alphatec competes with companies like Medtronic and Stryker.

Comparison to Industry Standards

• The use of multi-year vesting schedules (up to three years for time-based RSUs) is consistent with industry best practices for executive retention and long-term incentive plans, similar to those seen at comparable medical device companies.
• Performance-based RSUs with specific stock price hurdles and operational metrics are a robust form of incentive compensation, often employed by growth-oriented companies. For instance, companies like NuVasive (now part of Globus Medical) and Zimmer Biomet frequently utilize similar structures to motivate executives towards ambitious financial and strategic goals.
• The grant of RSUs in lieu of a cash bonus is a common strategy to conserve cash while still providing competitive compensation, particularly for companies focused on reinvesting in growth or managing cash flow.

Stakeholder Impact

• Shareholders: Potential future dilution upon RSU vesting, but also potential benefit from management's incentivized efforts to increase stock price and operational performance.
• Employees: Reinforces a culture of performance-based compensation and long-term incentives for key personnel.

Next Steps

• Vesting of 205,094 RSUs in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
• Vesting of 84,918 RSUs in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029.
• Vesting of 12,840 RSUs on December 4, 2026.
• Achievement of a 30-day average trading price of at least $25.00 per share by December 31, 2028, for certain performance-based RSUs.
• Achievement of certain operational metrics by December 31, 2028, for certain performance-based RSUs.
• Achievement of a 30-day average trading price of at least $36.00 per share by December 31, 2030, for certain performance-based RSUs.
• Achievement of certain operational metrics by December 31, 2030, for certain performance-based RSUs.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation through RSU grants, including performance-based awards. While the grants align management incentives with shareholder value and reflect confidence in future growth, they are not typically a standalone catalyst for significant short-term price movement. The long-term performance targets are positive, but the immediate impact is neutral, warranting a 'hold' recommendation for existing investors to observe future operational and stock price performance.

Keywords

Alphatec Holdings, ATEC, SEC Form 4, Restricted Stock Units, RSU Grant, Executive Compensation, Performance-Based Awards, Stock Options, Corporate Governance, Insider Transaction